935696-96-1Relevant articles and documents
Preparation method of key intermediate 4-amino-5-halobenzofuran-7-carboxylic acid of 5-HT4 receptor stimulant
-
Paragraph 0044; 0049-0051, (2020/03/02)
The invention discloses a preparation method of a key intermediate 4-amino-5-halobenzofuran-7-carboxylic acid of a 1,5-HT4 receptor stimulant, belonging to the field of organic synthesis. According tothe preparation method, para-protected amino-o-hydroxybenzoic acid/hydroxybenzoate, a halogenating reagent and triethyl acetenyl silicon are used as main raw materials, and a three-step reaction is performed to obtain the 4-amino-5-halobenzofuran-7-carboxylic acid. The method has the advantages of simple process operation, short reaction steps, easy separation of the intermediate, total yield ofmore than 51%, usage cheap and easily available raw materials and greatly reduced production cost; and thus, the method has obvious competitive advantages.
AMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS
-
, (2016/09/22)
The present invention relates to compounds of formula (I), including their stereoisomers and pharmaceutically acceptable salts. This invention also relates to methods of making such compounds and pharmaceutical compositions comprising such compounds. The compounds of this invention are useful in the treatment of various disorders that are related to 5-hydroxytryptamine 4 (5-HT4) receptor.
NOVEL COMPOUND
-
Page/Page column 18-19, (2008/06/13)
The present invention relates to a novel benzofuran carboxamide derivative having pharmacological activity, to processes for its preparation, to compositions containing it and to its use in the treatment of diseases treatable by 5-HT4 agonism.
4-AMINO-BENZAMIDE DERIVATIVES AS 5-HT4 RECEPTOR AGONISTS FOR THE TREATMENT OF GASTROINTESTINAL, NEUROLOGICAL AND CARDIOVASCULAR DISORDERS
-
Page/Page column 21, (2010/11/28)
The present invention relates to novel benzamide derivatives of formula (I) having pharmacological activity, to processes for their preparation, to compositions containing them and to their use in the treatment of diseases treatable by 5-HT4 agonism.